CD86 and neoplasm: When mature phenotypes of lineage-CD11c+MHC-II+ splenic DCs in the spleens isolated from each group (normal group, PBS-administered tumor-bearing group, Ocs-P-administered tumor-bearing group) were assessed, PBS-administered tumor-bearing mice showed lower expression levels of surface molecules (CD80, CD86, MHC-I) in lineage-CD11c+MHC-II+ splenic DCs compared with normal mice.